Trexquant Investment LP Acquires 167,907 Shares of Exelixis, Inc. (NASDAQ:EXEL)

Trexquant Investment LP lifted its stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 39.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 595,146 shares of the biotechnology company's stock after purchasing an additional 167,907 shares during the period. Trexquant Investment LP owned 0.21% of Exelixis worth $19,818,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of the stock. Tri Ri Asset Management Corp purchased a new stake in Exelixis in the third quarter worth about $4,396,000. Blue Trust Inc. lifted its stake in shares of Exelixis by 134.7% in the 4th quarter. Blue Trust Inc. now owns 14,302 shares of the biotechnology company's stock valued at $476,000 after purchasing an additional 8,208 shares during the period. Range Financial Group LLC bought a new stake in shares of Exelixis during the fourth quarter valued at approximately $994,000. FMR LLC grew its stake in Exelixis by 6.1% in the third quarter. FMR LLC now owns 2,462,072 shares of the biotechnology company's stock worth $63,891,000 after purchasing an additional 140,568 shares during the period. Finally, Allspring Global Investments Holdings LLC raised its holdings in Exelixis by 82.1% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,562,790 shares of the biotechnology company's stock worth $52,884,000 after purchasing an additional 704,786 shares in the last quarter. Institutional investors own 85.27% of the company's stock.

Analyst Ratings Changes

A number of brokerages have recently commented on EXEL. Wells Fargo & Company downgraded shares of Exelixis from an "overweight" rating to an "equal weight" rating and set a $36.00 target price on the stock. in a research report on Monday, February 24th. Guggenheim reaffirmed a "buy" rating and set a $42.00 target price on shares of Exelixis in a research note on Wednesday, February 12th. Oppenheimer cut Exelixis from an "outperform" rating to a "market perform" rating and dropped their price target for the stock from $41.00 to $33.00 in a research report on Friday, January 24th. UBS Group upped their price target on Exelixis from $30.00 to $34.00 and gave the stock a "neutral" rating in a research note on Tuesday, January 28th. Finally, Morgan Stanley upgraded Exelixis from an "equal weight" rating to an "overweight" rating and lifted their price objective for the company from $30.00 to $40.00 in a research note on Monday, January 27th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $37.59.

Remove Ads

Insider Transactions at Exelixis

In other Exelixis news, EVP Patrick J. Haley sold 52,636 shares of the business's stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $36.98, for a total transaction of $1,946,479.28. Following the completion of the sale, the executive vice president now owns 303,310 shares of the company's stock, valued at approximately $11,216,403.80. The trade was a 14.79 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Mary C. Beckerle sold 12,210 shares of the firm's stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $34.88, for a total value of $425,884.80. Following the completion of the transaction, the director now directly owns 30,406 shares in the company, valued at $1,060,561.28. This trade represents a 28.65 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 140,343 shares of company stock worth $5,177,234 in the last three months. Corporate insiders own 2.85% of the company's stock.

Exelixis Stock Down 5.8 %

NASDAQ:EXEL traded down $2.11 on Friday, hitting $34.57. The stock had a trading volume of 2,944,993 shares, compared to its average volume of 2,149,678. The business's 50-day simple moving average is $35.90 and its two-hundred day simple moving average is $33.60. The stock has a market cap of $9.68 billion, a price-to-earnings ratio of 19.53, a price-to-earnings-growth ratio of 1.13 and a beta of 0.57. Exelixis, Inc. has a 52-week low of $20.14 and a 52-week high of $40.02.

Exelixis (NASDAQ:EXEL - Get Free Report) last announced its earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%. As a group, equities research analysts anticipate that Exelixis, Inc. will post 2.04 EPS for the current year.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.